



DERMATOLOGY

E-Scribe and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: _____ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: _____

PATIENT INFORMATION

Patient Name: _____ Male: ☐ Prescriber: _____

Address: _____ Female: ☐ Office Contact: _____

City: _____ State: _____ Zip: _____ Address: _____

Email: _____ City: _____ State: _____ Zip: _____

Last 4 of SSN: _____ DOB: _____ Phone: _____ Fax: _____

Translator: Yes ☐ No ☐ Language: _____ DEA/NPI #: _____

Patient interested in: Support Programs ☐ Ancillary Supplies ☐ Signature: _____ Date: _____

PRESCRIBER INFORMATION

INSURANCE INFORMATION - PLEASE FAX A COPY OF FRONT & BACK OF PRESCRIPTION CARD

CLINICAL INFORMATION

Diagnosis: _____ ICD-10 Code: _____

Has the patient been treated previously for this condition: Yes ☐ No ☐ Height: _____ ft _____ in Weight: _____ lbs

Allergies: _____ Medications On: _____

Other Notes: _____ Medications Failed: _____

ACTEMRA®

Dosage/Strength:

- ☐ 162mg/0.9ml prefilled syringe
☐ 162mg/0.9ml ACTPen autoinjector

Directions:

- ☐ Inject _____ SC every other week
☐ Inject _____ SC every week
☐ Other: _____

Quantity: ☐ 4-week supply

Refill:

ADBRY®

Dosage/Strength:

- ☐ 150mg/ml prefilled syringe

Directions:

Initial Loading Dose:

- ☐ Inject 600mg (4 - 150mg injections) SC on day 1

Maintenance Dose:

- ☐ Inject 300mg (2 - 150mg) SC every 2 weeks
Maintenance Dose option for patients weighing <100kg, stable on Adbry >16 weeks with clear or almost clear skin:
☐ Inject 300mg (2 - 150mg) SC every 4 weeks

Quantity: ☐ 4-week supply

Refill:

AMJEVITA® CITRATE-FREE (HUMIRA BIOSIMILAR)

Dosage/Strength:

- ☐ 20mg/0.4ml prefilled syringe
☐ 40mg/0.8ml prefilled syringe
☐ 40mg/0.8ml prefilled pen

Directions:

- ☐ Inject 40mg every other week
☐ Inject 40mg every week

Quantity:

Refill:

BOTOX

Dosage/Strength:

- ☐ 100U Vial ☐ 200U Vial

Directions:

- ☐ Inject _____ units every _____ weeks

Quantity:

Refill:

CIBINQO®

Dosage/Strength:

- ☐ 50mg tablet ☐ 100mg tablet
☐ 200mg tablet

Directions:

- ☐ 1 tablet by mouth once daily

Quantity: ☐ 30-day supply ☐ 90-day supply

Refill:

CIMZIA®

Dosage/Strength:

- ☐ 200mg/ml prefilled syringe ☐ Starter Kit

Directions:

Loading Dose:

- ☐ Inject 400mg SC at weeks 0, 2, 4

Maintenance Dose:

- ☐ Inject 200mg SC every other week
(option for patients <90kg body weight)
☐ Inject 400mg SC every 4 weeks
☐ Other: _____

Quantity: ☐ 4-week supply

Refill:

COSENTYX®

Dosage/Strength:

- ☐ 75mg syringe ☐ 150mg pen
☐ 150mg syringe

Directions:

Loading Dose:

- ☐ Inject 150mg at weeks 0, 1, 2, 3, 4
☐ Inject 300mg at weeks 0, 1, 2, 3, 4

Maintenance Dose:

- ☐ Inject 150mg every 4 weeks
☐ Inject 300mg every 4 weeks

Quantity:

- ☐ 5-week supply (Loading)
☐ 4-week supply (Maintenance)

Refill:

NATIONALLY ACCREDITED. 100% EMPLOYEE OWNED. WWW.NOBLEHEALTHSERVICES.COM

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. Q320231



DERMATOLOGY

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: _____ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: _____

PATIENT INFORMATION

Patient Name: _____ Male: ☐ Prescriber: _____

Address: _____ Female: ☐ Office Contact: _____

City: _____ State: _____ Zip: _____ Address: _____

Email: _____ City: _____ State: _____ Zip: _____

Last 4 of SSN: _____ DOB: _____ Phone: _____ Fax: _____

Translator: Yes ☐ No ☐ Language: _____ DEA/NPI #: _____

Patient interested in: Support Programs ☐ Ancillary Supplies ☐ Signature: _____ Date: _____

PRESCRIBER INFORMATION

INSURANCE INFORMATION - PLEASE FAX A COPY OF FRONT & BACK OF PRESCRIPTION CARD

CLINICAL INFORMATION

Diagnosis: _____ ICD-10 Code: _____

Has the patient been treated previously for this condition: Yes ☐ No ☐ Height: _____ ft _____ in Weight: _____ lbs

Allergies: _____ Medications On: _____

Other Notes: _____ Medications Failed: _____

DUOBRIL®

Dosage/Strength: ☐ 0.01%/0.045% lotion

Directions:

☐ Apply a thin layer of lotion topically to the affected area(s) once daily

Quantity: ☐ 100 gram tube

Refill:

DUPIXENT®

Dosage/Strength:

☐ 200mg/1.14ml single-dose prefilled syringe

☐ 200mg/1.14ml single-dose prefilled pen

☐ 300mg/2ml single-dose prefilled syringe

☐ 300mg/2ml single-dose prefilled pen

Prefilled pens are approved for use in patients 2 years of age and older.

Directions:

Adult (and Pediatric Patients >60 Kg)

Initial Loading Dose:

☐ Inject 600mg (2-300mg injections) SC on day 1

Maintenance Dose:

☐ Inject 300mg SC every 2 weeks

Pediatric Patients 6 months to 5 years of age

Body Weight 5kg to <15kg Loading & Maintenance Dose:

☐ Inject 200mg SC every 4 weeks

Body Weight 15kg to <30kg Loading & Maintenance Dose:

☐ Inject 300mg SC every 4 weeks

Pediatric Patients 6 years to 17 years of age

Body Weight 15kg to <30kg Loading Dose:

☐ Inject 600mg (2-300mg injections) SC on day 1

Body Weight 15kg to <30kg Maintenance Dose:

☐ Inject 200mg SC every 4 weeks

☐ Inject 300mg SC every 4 weeks

Body Weight 30kg to <60kg Loading Dose:

☐ Inject 400mg (2-200mg injections) SC on day 1

Body Weight 30kg to <60kg Maintenance Dose:

☐ Inject 200mg SC every 2 weeks

Body Weight 60kg or more Loading Dose:

☐ Inject 600mg (2-300mg injections) SC on day 1

Body Weight 60kg or more Maintenance Dose:

☐ Inject 300mg SC every 2 weeks

Quantity: ☐ 4-week supply

Refill:

CYLTEZO® CITRATE-FREE (HUMIRA INTERCHANGEABLE BIOSIMILAR)

Dosage/Strength:

☐ 20mg/0.4ml prefilled syringe

☐ 40mg/0.8ml prefilled syringe

☐ 40mg/0.8ml prefilled pen

Directions:

☐ Inject 40mg every other week

☐ Inject 40mg every week

Quantity: _____

Refill:

ENBREL® AND ENBREL® MINI

Dosage/Strength:

☐ 25mg/0.5ml prefilled syringe

☐ 50mg/ml single-use prefilled syringe

☐ 50mg/ml SureClick autoinjector

☐ 25mg vial

☐ 50mg Enbrel® Mini single-dose prefilled cartridge

Directions:

☐ Inject 25mg SC twice a week (72-96 hrs apart)

☐ Inject 50mg SC twice a week (72-96 hrs apart)

☐ Inject 50mg SC once a week

☐ Other: _____

Quantity: ☐ 4-week supply

Refill:

HADLIMA® (HUMIRA BIOSIMILAR)

Dosage/Strength:

☐ 40mg/0.4ml syringe

☐ 40mg/0.8ml syringe

☐ 40mg/0.4ml Pushtouch syringe

☐ 40mg/0.8ml Pushtouch syringe

Directions:

☐ Inject 40mg every other week

☐ Inject 40mg every week

Quantity: _____

Refill:

NATIONALLY ACCREDITED. 100% EMPLOYEE OWNED. WWW.NOBLEHEALTHSERVICES.COM

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. Q320231



DERMATOLOGY

E-Scribe and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: _____ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: _____

PATIENT INFORMATION

Patient Name: _____ Male: ☐ Prescriber: _____

Address: _____ Female: ☐ Office Contact: _____

City: _____ State: _____ Zip: _____ Address: _____

Email: _____ City: _____ State: _____ Zip: _____

Last 4 of SSN: _____ DOB: _____ Phone: _____ Fax: _____

Translator: Yes ☐ No ☐ Language: _____ DEA/NPI #: _____

Patient interested in: Support Programs ☐ Ancillary Supplies ☐ Signature: _____ Date: _____

PRESCRIBER INFORMATION

INSURANCE INFORMATION - PLEASE FAX A COPY OF FRONT & BACK OF PRESCRIPTION CARD

CLINICAL INFORMATION

Diagnosis: _____ ICD-10 Code: _____

Has the patient been treated previously for this condition: Yes ☐ No ☐ Height: _____ ft _____ in Weight: _____ lbs

Allergies: _____ Medications On: _____

Other Notes: _____ Medications Failed: _____

HUMIRA® CITRATE-FREE

Dosage/Strength:

- ☐ 40mg/0.4ml pen
☐ 40mg/0.4ml prefilled syringe

Directions:

- ☐ Inject 40mg SC every other week
☐ Inject 40mg SC once a week

Quantity: ☐ 4-week supply

Refill:

HUMIRA® CITRATE-FREE HS STARTER KIT

Dosage/Strength: ☐ 80mg/0.8ml pen x3

Directions:

Loading Dose:

- ☐ Inject 160mg SC day 1, 80mg day 15, maintenance beginning on day 29
☐ Inject 80mg SC day 1, 80mg day 2, 80mg day 15, maintenance beginning on day 29

Quantity: ☐ 4-week supply

Refill:

HUMIRA® CITRATE-FREE PSORIASIS/UVEITIS STARTER KIT

Dosage/Strength:

- ☐ 80mg/0.8ml pen ☐ 40mg/0.4ml pen x2

Directions:

Loading Dose:

- ☐ Inject 80mg SC day 1, 80mg day 2, 40mg day 8, 40mg maintenance beginning on day 22

Quantity: ☐ 4-week supply

Refill:

ILUMYA®

Dosage/Strength:

- ☐ 100mg/ml single-dose prefilled syringe

Directions:

- ☐ Inject 100mg SC at weeks 0,4, and every 12 weeks thereafter

Quantity: ☐ 4-week supply

Refill:

INFLECTRA®

Dosage/Strength: ☐ 100mg vial

Directions:

Loading Dose:

- ☐ Infuse _____ mg (5mg/kg) at 0, 2, 6 weeks then every 8 weeks thereafter via IV

Maintenance Dose:

- ☐ Infuse _____ mg (5mg/kg) every 8 weeks via IV

Quantity: _____ vials

Refill:

OLUMIANT®

Dosage/Strength: ☐ 2mg tablet ☐ 4mg tablet

Directions: ☐ 1 tablet by mouth once daily

Quantity: _____

Refill: _____

OPZELURA™

Dosage/Strength: ☐ 1.5% topical cream

Directions:

- ☐ Apply a thin layer topically twice daily to affected areas of up to 20% of body surface area.

Do not use more than one 60 gram tube per week or one 100 gram tube every 2 weeks.

Quantity: ☐ 60 gram tube ☐ 100 gram tube

Refill:

OTEZLA®

Dosage/Strength:

- ☐ 28-day starter pack titration ☐ 30mg

Directions:

- ☐ Initial Dose titration per starter pack
☐ Take 30mg by mouth twice daily

Quantity:

- ☐ Starter Kit ☐ Bottle of 60

Refill:

NATIONALLY ACCREDITED. 100% EMPLOYEE OWNED. WWW.NOBLEHEALTHSERVICES.COM

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. Q320231



DERMATOLOGY

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: _____ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: _____

PATIENT INFORMATION

Patient Name: _____ Male: ☐ Prescriber: _____

Address: _____ Female: ☐ Office Contact: _____

City: _____ State: _____ Zip: _____ Address: _____

Email: _____ City: _____ State: _____ Zip: _____

Last 4 of SSN: _____ DOB: _____ Phone: _____ Fax: _____

Translator: Yes ☐ No ☐ Language: _____ DEA/NPI #: _____

Patient interested in: Support Programs ☐ Ancillary Supplies ☐ Signature: _____ Date: _____

PRESCRIBER INFORMATION

INSURANCE INFORMATION - PLEASE FAX A COPY OF FRONT & BACK OF PRESCRIPTION CARD

CLINICAL INFORMATION

Diagnosis: _____ ICD-10 Code: _____

Has the patient been treated previously for this condition: Yes ☐ No ☐ Height: _____ ft _____ in Weight: _____ lbs

Allergies: _____ Medications On: _____

Other Notes: _____ Medications Failed: _____

OTREXUP®

Dosage/Strength:

- ☐ 10mg/0.4ml autoinjector
- ☐ 12.5mg/0.4ml autoinjector
- ☐ 15mg/0.4ml autoinjector
- ☐ 17.5mg/0.4ml autoinjector
- ☐ 20mg/0.4ml autoinjector
- ☐ 22.5mg/0.4ml autoinjector
- ☐ 25mg/0.4ml autoinjector

Directions:

- ☐ Inject _____ mg SC once weekly
- ☐ Other:

Quantity: ☐ 4-week supply

Refill:

RASUVO®

Dosage/Strength:

- ☐ 7.5mg/0.15ml autoinjector
- ☐ 10mg/0.2ml autoinjector
- ☐ 12.5mg/0.25ml autoinjector
- ☐ 15mg/.3ml autoinjector
- ☐ 17.5mg/0.35ml autoinjector
- ☐ 20mg/0.4ml autoinjector
- ☐ 22.5mg/0.45ml autoinjector
- ☐ 25mg/0.5ml autoinjector
- ☐ 27.5mg/0.55ml autoinjector
- ☐ 30mg/0.6ml autoinjector

Directions:

- ☐ Inject _____ mg SC once weekly
- ☐ Other:

Quantity: ☐ 4-week supply

Refill:

RAYOS®

Dosage/Strength:

- ☐ 1mg tablet ☐ 2mg tablet ☐ 5mg tablet

Directions:

- ☐ Take _____ mg by mouth once per day
- ☐ Other:

Quantity: ☐ _____-day supply

Refill:

REMICADE®

Dosage/Strength: ☐ 100mg vial

Directions:

Loading Dose:

- ☐ Infuse _____ mg (5mg/kg) at 0, 2, 6 weeks, then every 8 weeks thereafter via IV

Maintenance Dose:

- ☐ Infuse _____ (5mg/kg) every 8 weeks via IV
- ☐ Infuse _____ (5mg/kg) every _____ weeks via IV
- ☐ Other:

Quantity: ☐ _____ vials

Refill:

RENFLEXIS®

Dosage/Strength: ☐ 100mg vial

Directions:

Loading Dose:

- ☐ 5mg/kg (Dose _____ mg) IV at weeks 0, 2, 6 then every 8 weeks thereafter

Maintenance Dose:

- ☐ 5mg/kg (Dose _____ mg) IV every 8 weeks
- ☐ IV _____ every _____ weeks
- ☐ Other:

Quantity: ☐ _____ vials

Refill:

RINVOQ™

Dosage/Strength: ☐ 15mg tablet ☐ 30mg tablet

Directions: ☐ Take one tablet by mouth once daily

Quantity: ☐ 30-day supply

Refill:

SILIQ™

Dosage/Strength:

☐ 210mg/1.5ml prefilled syringe

Directions:

- ☐ Inject 210mg SC at weeks 0, 1, 2 and 210mg SC every 2 weeks thereafter

Quantity:

- ☐ Starter Dose (3 syringes)
- ☐ Maintenance Dose (2 syringes)

Refill:

NATIONALLY ACCREDITED. 100% EMPLOYEE OWNED. WWW.NOBLEHEALTHSERVICES.COM

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. Q320231



DERMATOLOGY

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: _____ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: _____

PATIENT INFORMATION

Patient Name: _____ Male: ☐ Prescriber: _____

Address: _____ Female: ☐ Office Contact: _____

City: _____ State: _____ Zip: _____ Address: _____

Email: _____ City: _____ State: _____ Zip: _____

Last 4 of SSN: _____ DOB: _____ Phone: _____ Fax: _____

Translator: Yes ☐ No ☐ Language: _____ DEA/NPI #: _____

Patient interested in: Support Programs ☐ Ancillary Supplies ☐ Signature: _____ Date: _____

PRESCRIBER INFORMATION

INSURANCE INFORMATION - PLEASE FAX A COPY OF FRONT & BACK OF PRESCRIPTION CARD

CLINICAL INFORMATION

Diagnosis: _____ ICD-10 Code: _____

Has the patient been treated previously for this condition: Yes ☐ No ☐ Height: _____ ft _____ in Weight: _____ lbs

Allergies: _____ Medications On: _____

Other Notes: _____ Medications Failed: _____

SIMPONI®

Dosage/Strength:

- ☐ 50mg/0.5ml prefilled syringe
- ☐ 100mg/1ml prefilled syringe
- ☐ 50mg/0.5ml SmartJect autoinjector
- ☐ 100mg/1ml SmartJect autoinjector

Directions:

- ☐ Inject 50mg SC once a month
- ☐ Inject 100mg SC once a month
- ☐ Inject 200mg SC at week 0, 100mg at week 2 then 100mg every 4 weeks thereafter

Quantity: ☐ 4-week supply

Refill:

SKYRIZI®

Dosage/Strength:

- ☐ 150mg/mL prefilled syringe
- ☐ 150mg/mL pen

Directions:

Loading Dose:

- ☐ Inject 150mg SC at weeks 0, 4, and every 12 weeks thereafter

Maintenance Dose:

- ☐ Inject 150mg SC every 12 weeks

Quantity: ☐ 1 prefilled syringe/pen

Refill:

STELARA®

Dosage/Strength:

- ☐ 45mg/0.5ml prefilled syringe
- ☐ 90mg/ml prefilled syringe

Directions:

Patients weighing <100kg:

- ☐ Inject 45mg SC at 0 and 4 weeks, then every 12 weeks thereafter

Maintenance Dose:

- ☐ Inject 90mg SC at 0 and 4 weeks, then every 12 weeks thereafter

Quantity:

- ☐ 2 syringes (Loading)
- ☐ 1 syringe (Maintenance)

Refill:

SOTYKYU®

Dosage/Strength: ☐ 6mg tablet

Directions:

- ☐ Take 1 tablet (6mg) by mouth once daily

Quantity: ☐ 30-day supply

Refill:

TALTZ®

Dosage/Strength:

- ☐ 80mg/ml single-dose prefilled autoinjector
- ☐ 80mg/ml single-dose prefilled syringe

Directions:

Loading Dose:

- ☐ Inject 160mg SC at week 0 followed by 80mg SC on weeks 2, 4, 6, 8, 10, 12

Maintenance Dose:

- ☐ Inject 80mg SC every 4 weeks

Quantity:

- ☐ 3 syringes/pens ☐ 2 syringes/pens
- ☐ 1 syringe/pen

Refill:

TREMFYA®

Dosage/Strength:

- ☐ 100mg/ml prefilled syringe
- ☐ 100mg/ml prefilled autoinjector

Directions:

Loading Dose:

- ☐ Inject 100mg SC at weeks 0, 4, and every 8 weeks thereafter

Maintenance Dose:

- ☐ Inject 100mg SC every 8 weeks

Quantity:

- ☐ 4 week supply (Loading)
- ☐ 8 week supply (Maintenance)

Refill:

NATIONALLY ACCREDITED. 100% EMPLOYEE OWNED. WWW.NOBLEHEALTHSERVICES.COM

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. Q320231



DERMATOLOGY

E-SCRIBE and FAX ENROLLMENT FORM

☐ **NOBLE NORTHEAST:** E-Scribe: **NOBLE** | Fax: **888-842-3977** | Tel: 888-843-2040

☐ **NOBLE SOUTHEAST:** E-Scribe: **NOBLEMS/TRANSCRIPT** | Fax: **601-420-4040** | Tel: 866-420-4041

Delivery Needed By: _____ Deliver to: ☐ Patient's Home ☐ Physician's Office ☐ Other: _____

PATIENT INFORMATION

Patient Name: _____ Male: ☐ Prescriber: _____

Address: _____ Female: ☐ Office Contact: _____

City: _____ State: _____ Zip: _____ Address: _____

Email: _____ City: _____ State: _____ Zip: _____

Last 4 of SSN: _____ DOB: _____ Phone: _____ Fax: _____

Translator: Yes ☐ No ☐ Language: _____ DEA/NPI #: _____

Patient interested in: Support Programs ☐ Ancillary Supplies ☐ Signature: _____ Date: _____

INSURANCE INFORMATION - PLEASE FAX A COPY OF FRONT & BACK OF PRESCRIPTION CARD

CLINICAL INFORMATION

Diagnosis: _____ ICD-10 Code: _____

Has the patient been treated previously for this condition: Yes ☐ No ☐ Height: _____ ft _____ in Weight: _____ lbs

Allergies: _____ Medications On: _____

Other Notes: _____ Medications Failed: _____

VTAMA®

Dosage/Strength: ☐ 1% topical cream

Directions:

☐ Apply a thin layer to affected areas once daily

Quantity: ☐ 60 gram tube

Refill:

OTHER

Dosage/Strength:

Directions:

Quantity:

Refill:

NATIONALLY ACCREDITED. 100% EMPLOYEE OWNED. WWW.NOBLEHEALTHSERVICES.COM

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy. Q320231